|
|
| |
Investor/Media Contact
|
Home >> News & Events >> Media
Media
Feature Coverage
Dow Jones Business News (Nov. 8, 2012)
Amicus Therapeutics, its CEO Await Key Data on Rare Disease Drugs
BioWorld Today (Oct. 12, 2012)
Knowing When to Fold ‘Em: Amicus Phase II Pompe Data Solid
Quest: MDA’s Research & Health Magazine (Oct. 12, 2012)
Interim Results Suggest Chaperone Drug Enhances Enzyme Treatment in Pompe
Disease
BioWorld Today (July 19, 2012)
Amicus, GSK Extend Their Fabry Disease Collaboration
BioWorld Today (March 5, 2012)
Amicus Doubles Cash in $57M Offering; Amigal Data in 3Q12
Xconomy (Jan. 11, 2012)
Amicus Counts on Chaperone Technology to Enhance Rare Disease Treatments
Additional Coverage
Genetic Engineering & Biotechnology News (Nov. 13, 2012)
Top 13 Serial Entrepreneurs - Meet The Luckiest People in Biotech
NJBiz (Sept. 24, 2012)
Crowley's Return to Amicus Sparks New Investment
The Star-Ledger (Aug. 7, 2012)
Amicus Therapeutics Reports Narrower Loss, Higher Sales
Genetic Engineering & Biotechnology News (July 18, 2012)
GSK Invests $18.6M in Amicus to Expand Fabry Disease Drug Deal
Triangle Business Journal (July 18, 2012)
GlaxoSmithKline Ups Ownership Stake in N.J. Pharma
FierceBiotech (July 17, 2012)
GSK Boosts Stake in Amicus as PhIII Fabry Data Looms
Nature Medicine (Feb. 29, 2012)
Small Biotechs Raring to Cash in on the Orphan Disease Market
Press Release (Feb. 2, 2012)
The Michael J. Fox Foundation Pilots Partnering Program Between Awardees and Industry
Quest: MDA’s Research & Health Magazine (Dec. 19, 2011)
Trial Opens of ‘Pharmacological Chaperone’ in Pompe Disease
Quest: MDA’s Research & Health Magazine (Jan. 16, 2011)
Immunosuppression Induces Tolerance to Enzyme Treatment in Pompe Disease
|
Amicus Therapeutics is committed to improving the lives of patients and families affected by rare and orphan diseases.
|
|
|
|
|
